Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Breast Neoplasms 53Ovarian Neoplasms 4Prostatic Neoplasms 3Neoplasms 3Inflammatory Breast Neoplasms 3HER2-positive Breast Cancer 3Carcinoma, Non-Small-Cell Lung 3Stomach Neoplasms 2Solid Tumor 2Rectal Neoplasms 2Neoplasm Metastasis 2Colonic Neoplasms 2Urinary Bladder Neoplasms 1Solid Cancers 1Patient Preference 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neuroblastoma 1Neoplasms, Unknown Primary 1Multiple Endocrine Neoplasia 1Malignant Solid Neoplasm 1Lung Neoplasms 1Locally Advanced Breast Cancer 1Her2-Positive Breast Cancer 1HER2-positive Metastatic Breast Cancer 1HER2-positive Early Breast Cancer 1HER2-Positive Early Breast Cancer 1HER2 Positive Breast Cancer 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1

Interventions

Everolimus 16Octreotide 6pembrolizumab 5lanreotide 5Sunitinib 5Magnetic Resonance Spectroscopy 5gallium Ga 68 dotatate 4cabozantinib 4Nivolumab 4Carboplatin 4telotristat ethyl 3lenvatinib 3arginyllysine 3Specimen Handling 3Etoposide 3Erlotinib Hydrochloride 3Bevacizumab 3surufatinib 2pazopanib 2pasireotide 2lutetium Lu 177 dotatate 2amino-acid, glucose, and electrolyte solution 2X-Rays 2Temozolomide 2Sorafenib 2Phantoms, Imaging 2Paclitaxel 2Oxaliplatin 2Ipilimumab 2Doxorubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neuroendocrine Tumors × pertuzumab × Clear all
NCT00947167 2017-03-03

A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors

Stanford University

Phase 2 Terminated
4 enrolled 5 charts
CNSEndocrineNET

Adrenal Gland Neoplasms, Carcinoid Tumor, Multiple Endocrine Neoplasia, Neuroblastoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡